Cargando…

Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: A comparison of biweekly versus monthly administered neuroleptics

BACKGROUND: Long-acting injectable antipsychotics (LAIAs) have been developed to decrease medication nonadherence. LAIAs are usually given biweekly or monthly, with the exception of new 3-month and 6-week formulations. There has been no known evaluation regarding whether the frequency of LAIA formul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carr, Chelsea N., Hall, Colleen P., Roche-Desilets, Jennifer E., Burant, Christopher J., Fuller, Matthew A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	College of Psychiatric & Neurologic Pharmacists 2016
Materias:	Open Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007587/ https://www.ncbi.nlm.nih.gov/pubmed/29955478 http://dx.doi.org/10.9740/mhc.2016.09.248

Ejemplares similares

Hospitalizations and emergency room visits after initiation of long-acting injectable antipsychotics
por: Heesch, Chelsie B., et al.
Publicado: (2016)

Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder
por: Chou, Fabienne, et al.
Publicado: (2016)

Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review
por: Carr, Chelsea N., et al.
Publicado: (2016)

Diuretics: A possible keystone in upholding cognitive health
por: DeLoach, Tyler, et al.
Publicado: (2018)

Evaluation of provider response to positive depression screenings and physician attitudes on integrating psychiatric pharmacist services in primary care settings
por: Denson, Brittany H., et al.
Publicado: (2018)

Outcomes of patient education practices to optimize the safe use of lithium: A literature review
por: Zolezzi, Monica, et al.
Publicado: (2018)

Mania possibly linked with bupropion for smoking cessation: A case report
por: Dwyer, Stephanie, et al.
Publicado: (2016)

A pilot study evaluating the effectiveness of a medicines education group in a mental health inpatient setting: A UK perspective
por: White, Daniel, et al.
Publicado: (2018)

A design and focus group evaluation of dietary choices tools for an underserved population
por: McMorris, Tressa, et al.
Publicado: (2016)

A consumer-led intervention to improve pharmacists' attitudes toward mental illness
por: Rickles, Nathaniel M., et al.
Publicado: (2016)

Identification, assessment, and management of pain in patients with advanced dementia
por: Malotte, Kasey L., et al.
Publicado: (2016)

Suicide prevention in pharmaceutical education: Raising awareness with inspiring stories
por: Vincent, Philippe D., et al.
Publicado: (2016)

Evaluation of clinical pharmacy services within the primary care–mental health integration model at the Tuscaloosa Veterans Affairs Medical Center
por: Parikh, Mamta, et al.
Publicado: (2016)

Quantitative and economic analysis of clinical pharmacist interventions during rounds in an acute care psychiatric hospital
por: Gunterus, Alicia, et al.
Publicado: (2016)

Implementation and evaluation of a pharmacist-run mental health treatment clinic via clinical video telehealth
por: Leach, Molly, et al.
Publicado: (2016)

Management of migraine headaches in a chronic pain patient: A case report
por: Bach, Linda Lu, et al.
Publicado: (2016)

Using Photovoice to explore patients' experiences with mental health medication: A pilot study
por: Werremeyer, Amy B., et al.
Publicado: (2016)

Non–Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double‐Blind, Sham‐Controlled ACT1 Study
por: Silberstein, Stephen D., et al.
Publicado: (2016)

Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
por: Fiedler‐Kelly, Jill, et al.
Publicado: (2020)

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

No “Wearing‐Off Effect” Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long‐Term Study
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials
por: Ailani, Jessica, et al.
Publicado: (2022)

An Unusual Case of Neuroleptic Malignant Syndrome on a Stable Dose of Antipsychotic
por: Sanger, Emily, et al.
Publicado: (2023)

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study
por: Spierings, Egilius L. H., et al.
Publicado: (2021)

The need for efficient long-term neuroleptic treatment in schizophrenic patients and the place of long acting injectable antipsychotics
por: Möller, Hans-Jurgen
Publicado: (2010)

Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose
por: Korchia, Théo, et al.
Publicado: (2018)

Prescribing antipsychotics in child and adolescent psychiatry: guideline adherence
por: Dinnissen, Mariken, et al.
Publicado: (2020)

Disasters in Europe: Inviting authors to submit scientific and practical papers on disasters in their country
Publicado: (2000)

PDA (Prolonged Depolarizing Afterpotential) - Defective Mutants: The Story of nina's and ina's—pinta and santa maria, Too
por: Pak, William L., et al.
Publicado: (2012)

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
por: Tepper, Stewart J, et al.
Publicado: (2015)

A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine
por: Cady, Roger, et al.
Publicado: (2015)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

Severe Headache or Migraine History Is Inversely Correlated With Dietary Sodium Intake: NHANES 1999–2004
por: Pogoda, Janice M., et al.
Publicado: (2016)

Kinetic Oscillation Stimulation as Treatment of Acute Migraine: A Randomized, Controlled Pilot Study
por: Juto, Jan-Erik, et al.
Publicado: (2015)

The Neuropsychology of Cluster Headache: Cognition, Mood, Disability, and Quality of Life of Patients With Chronic and Episodic Cluster Headache
por: Torkamani, Mariam, et al.
Publicado: (2015)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

IMPROVING THE EFFECTIVENESS AND EFFICIENCY OF EVIDENCE PRODUCTION FOR HEALTH TECHNOLOGY ASSESSMENT
por: Facey, Karen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_d1ejdou8b82ki2al3gs4b5a2rl